03:52:01 EDT Thu 25 Apr 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Lexagene Holdings Inc
Symbol C : LXG
Shares Issued 60,088,553
Close 2018-05-28 C$ 1.19
Recent Sedar Documents

Lexagene signs cancer tech deal with Stanford

2018-05-29 11:58 ET - News Release

Dr. Jack Regan reports

LEXAGENE ENTERS COLLABORATION TO INCORPORATE CANCER SEQUENCING TECHNOLOGY INTO A NEW PRODUCT

Lexagene Holdings Inc. has entered into an agreement with the Stanford University School of Medicine. The agreement involves using a targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with Lexagene's microfluidic instrument. "LexaGene's technology was originally designed for pathogen detection across very large markets -- I am thrilled to report that we are working to expand our technology's capability to include cancer diagnostics and next-generation sequencing," added Dr. Jack Regan, Lexagene's chief executive officer.

About Lexagene Holdings Inc.

Lexagene is a biotechnology company developing the very first easy-to-use fully automated pathogen detection platform that is open access, the LX6. The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.